- Medical - Devices
- Healthcare
-
1.24
EPS
-
61.39
P/E
-
112B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
300 BOSTON SCIENTIFIC WAY,MARLBOROUGH MA 01752-1234,508-683-4000
CEO
Mr. Michael F. Mahoney
Employess
48000
Sector
Healthcare
Industry
Medical - Devices
Website
https://www.bostonscientific.com
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Next Earnings Date
Oct. 24, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
31.73%
Fiscal Year End
12-31
IPO Date
1992-05-19
Growth Rates
| (avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
|---|---|---|---|---|
| Sales/Revenue | 7.14% | 7.71% | 12.83% | 12.29% |
| EPS | 30.18% | -2.25% | 134.72% | 140.00% |
| Equity | 11.42% | 17.19% | 7.95% | 9.71% |
| Cash | 14.83% | 42.74% | -20.69% | -6.79% |
| Return On Capital (ROIC) | 9.16% | 13.02% | 5.95% | 6.53% |
Debt
| year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Short Term Debt | 531 | 20 | 261 | 13 | 1,420 |
| Long Term Debt | 8,960 | 9,260 | 9,190 | 9,530 | 8,860 |
| LT Finance Leases | 395 | 352 | 395 | 408 | 282 |
| Shares Outstanding | 1,450 | 1,430 | 1,420 | 1,420 | 1,390 |
| Market Cap | 84,000 | 66,200 | 60,400 | 50,900 | 62,900 |
Price
News
Buy 5 Surging Old Economy Stocks to Tap Market Rally
1 monthFive old economy stocks with strong near-term potential are: NEM, GE, PFE, PGR, BSX.
zacks.com
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
1 monthWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com
HAE or BSX: Which Is the Better Value Stock Right Now?
1 monthInvestors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
3 Reasons Why Growth Investors Shouldn't Overlook Boston Scientific (BSX)
1 monthBoston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
zacks.com
Hypergrowth Heroes: 7 Stocks That Could 10X Your Money
2 monthsToday we will be looking at hypergrowth stocks with the potential to 10X your investment. All but one of the stocks discussed below has achieved hypergrowth – growing by 40% or more – over the last 12 months.
investorplace.com
Boston Scientific (BSX) Rides on Global Growth, Buyouts
2 monthsBoston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
zacks.com
Boston Scientific Elects David Habiger to Board of Directors
2 monthsMARLBOROUGH, Mass. , July 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David Habiger to its board of directors, effective immediately.
prnewswire.com
3 Record-Breaking Stocks With More Upside Ahead
2 months2024 has been a great year for U.S. indices, with the benchmark S&P 500 posting new all-time highs 38 times so far. The rally has been primarily driven by the tech sector, focusing on artificial intelligence (AI).
investorplace.com
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
2 monthsBoston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
zacks.com
Boston Scientific Profit and Sales Are Boosted by Cardiovascular Device Demand
2 monthsBoston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices.
investopedia.com
Boston Scientific Corporation (BSX) Q2 2024 Earnings Call Transcript
2 monthsBoston Scientific Corporation (NYSE:BSX ) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ET Company Participants Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Daniel J.
seekingalpha.com
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
2 monthsWhile the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com